Adams loses interim tag, is now CEO of Tabula Rasa

It’s official: Brian Adams was named CEO of Tabula Rasa HealthCare on Friday, when the company took off the interim tag he has had since assuming CEO duties in September 2022.

Adams, who previously served as the company’s co-president and chief financial officer, was also appointed to the company’s board of directors as a Class I director, effective immediately.

Tabula Rasa HealthCare, based in Moorestown, views itself as a leading health care technology company advancing the safe use of medications.

Board Chair Michael Purcell said Adams has brought stability to the organization and laid a strong foundation for both profitable growth and long-term value creation while serving in the interim role.

“Thanks to his deep industry experience and strong knowledge of our primary target markets, in particular the Program of All-Inclusive Care for the Elderly, PACE, he has also earned the respect of our clients, partners, team members and shareholders,” Purcell said. “The board’s decision to appoint Brian as the company’s CEO reflects its commitment to fostering a high-performing management team and retaining, rewarding and developing TRHC’s own talent. We firmly believe Brian is the right leader as we embark on the next chapter for the company.”

Adams said he is eager to continue.

“I greatly appreciate the board’s trust and belief in me, and I am honored to continue working alongside a talented management team and dedicated employee base,” he said. “Over the past few months, we have made significant strides refocusing our business around our solutions for PACE, our fastest growing market, and we are committed to advancing these offerings in order to support future growth and enhance our client experience.

“Our combination of solutions is not only relevant in PACE, but also to adjacent health care markets taking on financial risk and serving similar demographics, and I am excited to capitalize on these opportunities. The board and the leadership team are confident in our current market position and look forward to keeping the momentum going as we continue to make positive impacts on patient care for our clients.”